Teva Makes A Specialty M&A Play In Deal To Buy Auspex
This article was originally published in The Pink Sheet Daily
The Israeli generic drug company will gain a lead drug in development for movement disorders, including chorea associated with Huntington’s disease, with the $3.5 billion acquisition of Auspex Pharmaceuticals.
You may also be interested in...
Keeping Track: Teva's Austedo Clears US FDA, Merck Sitagliptin CV Outcomes Labeling Draws Complete Response
The latest drug development news and highlights from our FDA Performance Tracker.
FDA approved Teva’s Austedo (deutetrabenazine) for chorea associated with Huntington’s disease, with a warning on depression and suicidality similar to generic Xenazine, but other parts of the labeling points to advantages.
A second Phase III study testing the VMAT2 inhibitor in the indication was positive, positioning Teva for a neck-and-neck race to market against Neurocrine.